Staccato Loxapine Thorough QT/QTc Study

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the present Phase 1 study was to assess the cardiac safety of Staccato Loxapine administered to healthy volunteers in a 3 period crossover study.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Alexza Pharmaceuticals, Inc.
• Treatments: Loxapine; Moxifloxacin; Norgestimate, ethinyl estradiol drug combination

Criteria

Inclusion Criteria:

• Subjects who are in good general health and agree to use a medically acceptable and effective birth control method throughout the study.

Exclusion Criteria:

• Subjects who have taken prescription or nonprescription medication within 5 days of treatment,

• Subjects who have had an acute illness within the last 5 days of treatment,

• Subjects who are smokers, OR

• Subjects who have an ECG abnormality at baseline.